Change Healthcare Reports Mixed Q2 Earnings; Refrains From Issuing Guidance Due To OptumInsight Deal

Change Healthcare Inc's CHNG Q2 FY22 sales increased 10% to $826.76 million, missing the consensus of $837.36 million.
Solutions revenue was $774.2 million, up 10%, and Postage revenue sales increased 5% to $52.55 million.
Solutions revenue includes the impact of fair value adjustments to deferred revenue resulting from the McKesson exit, which reduced revenue recognized by $3.3 million.
The Company posted an adjusted EPS of $0.35, beating the consensus of $0.32.
Adjusted EBITDA reached $246.5 million, compared with $231.8 million a year ago.
The Company ended the quarter with approximately $80.4 million of cash and cash equivalents and about $4,662.4 million of total debt.
The Company and UnitedHealth Group UNH entered into an amendment to the Timing Agreement with the DOJ to complete the merger on February 22, 2022.
Due to the proposed transaction with OptumInsight, the Company did not provide financial guidance.
Price Action: CHNG shares are up 0.12% at $21.55 during the market session on the last check Wednesday.